Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Enter your email address below and subscribe to our newsletter

After observing discouraging phase 2 clinical data, Novartis has opted to terminate the clinical advancement of its geographic atrophy gene therapy candidate GT005, a product it acquired through the acquisition of Gyroscope Therapeutics. The announcement was officially disseminated by investment…

Iveric Bio, an Astellas Company, has joined forces with Eric Stonestreet, a two-time Emmy® award-winning actor, to raise awareness about geographic atrophy (GA), a type of age-related macular degeneration (AMD) leading to irreversible vision loss. Eric and his mother, Jamey,…

What Is Bull’s Eye Maculopathy? Bull’s Eye Maculopathy is a specific form of retinal disease characterized by changes in the pigmentation of the macular region of the retina, often presenting as a ‘bull’s eye’ pattern. The macula is the central…

The U.S. Centers for Medicare & Medicaid Services (CMS) have officially designated a specific J-code (J2781) for Apellis Pharmaceuticals’ Syfovre (pegcetacoplan injection), marking it as the first treatment for geographic atrophy (GA) secondary to age-related macular degeneration. This J-code for…

Parent company Astellas Pharma announced that Iveric Bio has received FDA approval for Izervay (avacincaptad pegol intravitreal solution) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). As a new complement C5 inhibitor, Izervay stands out as the sole…

Repeat corticosteroid injections were found to be more effective in improving vision for individuals with persistent or recurrent uveitis-related macular edema compared to methotrexate or ranibizumab intravitreal injections, according to a recent clinical trial. The corticosteroid treatment exhibited superior results…

The retinal pigment epithelium (RPE) and choroid, located behind the human retina, play crucial roles in vision, encompassing functions such as light absorption and providing oxygenated blood to photoreceptor cells. However, our current understanding of gene expressions within these cells…

Ascertain, a joint venture between Aegis Ventures and Northwell Holdings, has raised $12 million in seed funding to launch Optain, an AI company that utilizes retinal imaging for early disease detection and prevention. Optain’s AI technology analyzes data from a…

Tenpoint Therapeutics, a biotechnology company focused on vision-restoring engineered cell-based therapeutics and in vivo reprogramming for degenerative ocular diseases, has announced its launch with a $70 million Series A financing. The funding will be used to develop the company’s regenerative…

Naegis Pharmaceuticals Inc., a life sciences company specializing in inflammation and ophthalmology, announced the successful closure of a financing round to advance its lead compound, N0651, towards a Phase 2 clinical trial. This funding will support the compound’s progression through…